155 related articles for article (PubMed ID: 37644890)
1. A phase 1 evaluation of the safety and tolerability of niraparib in combination with everolimus in advanced ovarian and breast cancers.
Starks D; Rojas-Espaillat L; Meissner T; Elsey R; Xu B; Koenen M; Feng S; VanOosbree A; Slunecka J; Lee J; Williams CB
Cancer Med; 2023 Sep; 12(18):18654-18665. PubMed ID: 37644890
[TBL] [Abstract][Full Text] [Related]
2. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
Mirza MR; Åvall Lundqvist E; Birrer MJ; dePont Christensen R; Nyvang GB; Malander S; Anttila M; Werner TL; Lund B; Lindahl G; Hietanen S; Peen U; Dimoula M; Roed H; Ør Knudsen A; Staff S; Krog Vistisen A; Bjørge L; Mäenpää JU;
Lancet Oncol; 2019 Oct; 20(10):1409-1419. PubMed ID: 31474354
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24.
Mirza MR; Bergmann TK; Mau-Sørensen M; Christensen RD; Åvall-Lundqvist E; Birrer MJ; Jørgensen M; Roed H; Malander S; Nielsen F; Lassen U; Brøsen K; Bjørge L; Mäenpää J
Cancer Chemother Pharmacol; 2019 Oct; 84(4):791-798. PubMed ID: 31375879
[TBL] [Abstract][Full Text] [Related]
4. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
Sandhu SK; Schelman WR; Wilding G; Moreno V; Baird RD; Miranda S; Hylands L; Riisnaes R; Forster M; Omlin A; Kreischer N; Thway K; Gevensleben H; Sun L; Loughney J; Chatterjee M; Toniatti C; Carpenter CL; Iannone R; Kaye SB; de Bono JS; Wenham RM
Lancet Oncol; 2013 Aug; 14(9):882-92. PubMed ID: 23810788
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer.
Lee JS; Yost SE; Blanchard S; Schmolze D; Yin HH; Pillai R; Robinson K; Tang A; Martinez N; Portnow J; Wen W; Yim JH; Brauer HA; Ren Y; Luu T; Mortimer J; Yuan Y
Breast Cancer Res; 2019 Nov; 21(1):119. PubMed ID: 31703728
[TBL] [Abstract][Full Text] [Related]
6. Phase I dose escalation study of dual PI3K/mTOR inhibition by Sapanisertib and Serabelisib in combination with paclitaxel in patients with advanced solid tumors.
Starks DC; Rojas-Espaillat L; Meissner T; Williams CB
Gynecol Oncol; 2022 Sep; 166(3):403-409. PubMed ID: 35843739
[TBL] [Abstract][Full Text] [Related]
7. Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.
Konstantinopoulos PA; Waggoner S; Vidal GA; Mita M; Moroney JW; Holloway R; Van Le L; Sachdev JC; Chapman-Davis E; Colon-Otero G; Penson RT; Matulonis UA; Kim YB; Moore KN; Swisher EM; Färkkilä A; D'Andrea A; Stringer-Reasor E; Wang J; Buerstatte N; Arora S; Graham JR; Bobilev D; Dezube BJ; Munster P
JAMA Oncol; 2019 Aug; 5(8):1141-1149. PubMed ID: 31194228
[TBL] [Abstract][Full Text] [Related]
8. OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab.
Hardesty MM; Krivak TC; Wright GS; Hamilton E; Fleming EL; Belotte J; Keeton EK; Wang P; Gupta D; Clements A; Gray HJ; Konecny GE; Moore RG; Richardson DL
Gynecol Oncol; 2022 Aug; 166(2):219-229. PubMed ID: 35690498
[TBL] [Abstract][Full Text] [Related]
9. Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial.
Reiss KA; Mick R; Teitelbaum U; O'Hara M; Schneider C; Massa R; Karasic T; Tondon R; Onyiah C; Gosselin MK; Donze A; Domchek SM; Vonderheide RH
Lancet Oncol; 2022 Aug; 23(8):1009-1020. PubMed ID: 35810751
[TBL] [Abstract][Full Text] [Related]
10. Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer.
Singh J; Novik Y; Stein S; Volm M; Meyers M; Smith J; Omene C; Speyer J; Schneider R; Jhaveri K; Formenti S; Kyriakou V; Joseph B; Goldberg JD; Li X; Adams S; Tiersten A
Breast Cancer Res; 2014 Mar; 16(2):R32. PubMed ID: 24684785
[TBL] [Abstract][Full Text] [Related]
11. A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy.
Hurvitz SA; Dalenc F; Campone M; O'Regan RM; Tjan-Heijnen VC; Gligorov J; Llombart A; Jhangiani H; Mirshahidi HR; Tan-Chiu E; Miao S; El-Hashimy M; Lincy J; Taran T; Soria JC; Sahmoud T; André F
Breast Cancer Res Treat; 2013 Oct; 141(3):437-46. PubMed ID: 24101324
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
Oncologist; 2012; 17(1):13. PubMed ID: 22210086
[TBL] [Abstract][Full Text] [Related]
13. Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer.
Vinayak S; Tolaney SM; Schwartzberg L; Mita M; McCann G; Tan AR; Wahner-Hendrickson AE; Forero A; Anders C; Wulf GM; Dillon P; Lynce F; Zarwan C; Erban JK; Zhou Y; Buerstatte N; Graham JR; Arora S; Dezube BJ; Telli ML
JAMA Oncol; 2019 Aug; 5(8):1132-1140. PubMed ID: 31194225
[TBL] [Abstract][Full Text] [Related]
14. Homologous Recombination Deficiency Testing to Inform Patient Decisions About Niraparib Maintenance Therapy for High-Grade Serous or Endometrioid Epithelial Ovarian Cancer: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2023; 23(5):1-188. PubMed ID: 37637244
[TBL] [Abstract][Full Text] [Related]
15. Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial.
Barretina-Ginesta MP; Monk BJ; Han S; Pothuri B; Auranen A; Chase DM; Lorusso D; Anderson C; Abadie-Lacourtoisie S; Cloven N; Braicu EI; Amit A; Redondo A; Shah R; Kebede N; Hawkes C; Gupta D; Woodward T; O'Malley DM; González-Martín A
Ther Adv Med Oncol; 2022; 14():17588359221126149. PubMed ID: 36172173
[TBL] [Abstract][Full Text] [Related]
16. A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.
Bitting RL; Healy P; Creel PA; Turnbull J; Morris K; Wood SY; Hurwitz HI; Starr MD; Nixon AB; Armstrong AJ; George DJ
Clin Genitourin Cancer; 2014 Aug; 12(4):241-50. PubMed ID: 24685058
[TBL] [Abstract][Full Text] [Related]
17. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Moore KN; Secord AA; Geller MA; Miller DS; Cloven N; Fleming GF; Wahner Hendrickson AE; Azodi M; DiSilvestro P; Oza AM; Cristea M; Berek JS; Chan JK; Rimel BJ; Matei DE; Li Y; Sun K; Luptakova K; Matulonis UA; Monk BJ
Lancet Oncol; 2019 May; 20(5):636-648. PubMed ID: 30948273
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial.
Fabbro M; Moore KN; Dørum A; Tinker AV; Mahner S; Bover I; Banerjee S; Tognon G; Goffin F; Shapira-Frommer R; Wenham RM; Hellman K; Provencher D; Harter P; Vázquez IP; Follana P; Pineda MJ; Mirza MR; Hazard SJ; Matulonis UA
Gynecol Oncol; 2019 Mar; 152(3):560-567. PubMed ID: 30638768
[TBL] [Abstract][Full Text] [Related]
19. Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 Trial.
Vignani F; Tambaro R; De Giorgi U; Giannatempo P; Bimbatti D; Carella C; Stellato M; Atzori F; Aieta M; Masini C; Hamzaj A; Ermacora P; Veccia A; Scandurra G; Gamba T; Ignazzi G; Pignata S; Di Napoli M; Lolli C; Procopio G; Pierantoni F; Zonno A; Santini D; Di Maio M;
Eur Urol; 2023 Jan; 83(1):82-89. PubMed ID: 36216658
[TBL] [Abstract][Full Text] [Related]
20. A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer.
Vlahovic G; Meadows KL; Hatch AJ; Jia J; Nixon AB; Uronis HE; Morse MA; Selim MA; Crawford J; Riedel RF; Zafar SY; Howard LA; O'Neill M; Meadows JJ; Haley ST; Arrowood CC; Rushing C; Pang H; Hurwitz HI
Oncologist; 2018 Jul; 23(7):782-790. PubMed ID: 29572245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
